Axon Enterprise is the most frequent co-covered peer, appearing in 1 of the 2 tracked stories. Across a 163-day span, the pace is roughly 0.1 stories per week. They are less corroborated than the beat average, carrying 3.5 original sources each against 3.7 for the same window.
Figures are computed live from our source-verified story record
— see our methodology for how impact and
sentiment are derived.
What the coverage shows about Supernus Pharmaceuticals
Axon Enterprise is the most frequent co-covered peer, appearing in 1 of the 2 tracked stories. Across a 163-day span, the pace is roughly 0.1 stories per week. They are less corroborated than the beat average, carrying 3.5 original sources each against 3.7 for the same window. Their average consequence score of 5.5 runs below the beat's 6.1 for that window. acquisition accounts for 1 of the 2 tracked stories, while 1 other category carries the remainder. We currently track 2 Healthcare stories that mention Supernus Pharmaceuticals, published between February 23, 2026 and August 4, 2026.
Stories tracked
2
Per week
0.1
Sources per story
3.5
Computed from the 2 stories linked to this entity, with beat comparisons drawn from all 973 Healthcare stories published in the same date window. Shares are omitted below five stories and comparisons below a twenty-story baseline.
Coverage cohort
Appears alongside
Other entities that clear the same relevance threshold in stories also covering Supernus Pharmaceuticals. Shared-story counts are live from our verified record — not editorial picks.
Supernus Pharmaceuticals is acquiring Indivior in an all-stock deal, assembling a portfolio of 11 FDA-approved CNS treatments. The merger targets $125 million in annual cost synergies and expands the company's footprint in neurology, addiction, and psychiatry. Meanwhile, Q2 revenue jumped 32% to $219 million, but a surprise net loss of $58.1 million casts a shadow over short-term integration risks.
Investors are bracing for Q4 2025 results from Axon Enterprise, Supernus Pharmaceuticals, and Corcept Therapeutics, with Axon looking to maintain its perfect revenue beat streak. While Axon dominates the public safety tech space, the pharmaceutical players face varying expectations regarding clinical pipelines and market penetration for core therapies.
